OtherBasic Science Investigations
Pharmacokinetics, Dosimetry, and Toxicity of the Targetable Atomic Generator, 225Ac-HuM195, in Nonhuman Primates
Matthias Miederer, Michael R. McDevitt, George Sgouros, Kim Kramer, Nai-Kong V. Cheung and David A. Scheinberg
Journal of Nuclear Medicine January 2004, 45 (1) 129-137;
Matthias Miederer
Michael R. McDevitt
George Sgouros
Kim Kramer
Nai-Kong V. Cheung
In this issue
Journal of Nuclear Medicine
Vol. 65, Issue 3
March 1, 2024
Pharmacokinetics, Dosimetry, and Toxicity of the Targetable Atomic Generator, 225Ac-HuM195, in Nonhuman Primates
Matthias Miederer, Michael R. McDevitt, George Sgouros, Kim Kramer, Nai-Kong V. Cheung, David A. Scheinberg
Journal of Nuclear Medicine Jan 2004, 45 (1) 129-137;
Related Articles
- No related articles found.
Cited By...
- Treatment of prostate cancer with CD46 targeted 225Ac alpha particle radioimmunotherapy
- [18F]-Labeled PARP-1 PET Imaging of PSMA Targeted Alpha Particle Radiotherapy Response
- Preclinical Evaluation of 213Bi- and 225Ac-Labeled Low-Molecular-Weight Compounds for Radiopharmaceutical Therapy of Prostate Cancer
- A Self-Assembling and Disassembling (SADA) Bispecific Antibody (BsAb) Platform for Curative Two-step Pretargeted Radioimmunotherapy
- Preclinical Evaluation of 203/212Pb-Labeled Low-Molecular-Weight Compounds for Targeted Radiopharmaceutical Therapy of Prostate Cancer
- Therapeutic Radiometals Beyond 177Lu and 90Y: Production and Application of Promising {alpha}-Particle, {beta}--Particle, and Auger Electron Emitters
- The Future of Radioligand Therapy: {alpha}, {beta}, or Both?
- Preclinical Evaluation of Multistep Targeting of Diasialoganglioside GD2 Using an IgG-scFv Bispecific Antibody with High Affinity for GD2 and DOTA Metal Complex
- Molecular Pathways: Targeted {alpha}-Particle Radiation Therapy
- Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model
- MIRD Pamphlet No. 22 (Abridged): Radiobiology and Dosimetry of {alpha}-Particle Emitters for Targeted Radionuclide Therapy
- Radioimmunotherapy of Breast Cancer Metastases with {alpha}-Particle Emitter 225Ac: Comparing Efficacy with 213Bi and 90Y
- A Pharmacokinetic Model for Radioimmunotherapy Delivered Through Cerebrospinal Fluid for the Treatment of Leptomeningeal Metastases
- Multidrug Resistance in Acute Myeloid Leukemia: Potential New Therapeutics
- Preclinical Evaluation of the {alpha}-Particle Generator Nuclide 225Ac for Somatostatin Receptor Radiotherapy of Neuroendocrine Tumors
- Phase I Study of Targeted Radioimmunotherapy for Leptomeningeal Cancers Using Intra-Ommaya 131-I-3F8
- 111In-Labeled Trastuzumab (Herceptin) Modified with Nuclear Localization Sequences (NLS): An Auger Electron-Emitting Radiotherapeutic Agent for HER2/neu-Amplified Breast Cancer
- Anti-CD45 Monoclonal Antibody YAML568: A Promising Radioimmunoconjugate for Targeted Therapy of Acute Leukemia
- Nuclear Localizing Sequences Promote Nuclear Translocation and Enhance the Radiotoxicity of the Anti-CD33 Monoclonal Antibody HuM195 Labeled with 111In in Human Myeloid Leukemia Cells
- Renal Tubulointerstitial Changes after Internal Irradiation with {alpha}-Particle-Emitting Actinium Daughters
- Melanoma Therapy via Peptide-Targeted {alpha}-Radiation
- Treatment of Neuroblastoma Meningeal Carcinomatosis with Intrathecal Application of {alpha}-Emitting Atomic Nanogenerators Targeting Disialo-Ganglioside GD2
- Alpha-Particle Emitting Atomic Generator (Actinium-225)-Labeled Trastuzumab (Herceptin) Targeting of Breast Cancer Spheroids: Efficacy versus HER2/neu Expression